{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:08:59Z","timestamp":1784005739309,"version":"3.55.0"},"reference-count":45,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_pp-2023-0004_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Pressurized intraperitoneal aerosol chemotherapy (PIPAC) gives encouraging results in the treatment of peritoneal metastasis (PM). The current recommendations require at least 3 sessions of PIPAC. However, some patients do not complete the full treatment course and stop after only 1 or 2 procedures, hence the limited benefit. A literature review was performed, with search terms including \u201cPIPAC\u201d and \u201cpressurised intraperitoneal aerosol chemotherapy.\u201d<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_pp-2023-0004_abs_002\">\n                  <jats:title>Content<\/jats:title>\n                  <jats:p>Only articles describing the causes for premature termination of the PIPAC treatment were analysed. The systematic search identified 26 published clinical articles related to PIPAC and reporting causes for stopping PIPAC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_pp-2023-0004_abs_003\">\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>The series range from 11 to 144 patients, with a total of 1352 patients treated with PIPAC for various tumours. A total of 3088 PIPAC treatments were performed. The median number of PIPAC treatments per patient was 2.1, the median PCI score at the time of the first PIPAC was 19 and the number of patients who did not complete the recommended 3 sessions of PIPAC was 714 (52.8%). Disease progression was the main reason for early termination of the PIPAC treatment (49.1%). The other causes were death, patients\u2019 wishes, adverse events, conversion to curative cytoreductive surgery and other medical reasons (embolism, pulmonary infection, etc\u2026).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_pp-2023-0004_abs_004\">\n                  <jats:title>Outlook<\/jats:title>\n                  <jats:p>Further investigations are necessary to better understand the causes for interrupting PIPAC treatment and also improving the selection of patients who are most likely to benefit from PIPAC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/pp-2023-0004","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T23:25:34Z","timestamp":1681946734000},"page":"45-53","source":"Crossref","is-referenced-by-count":14,"title":["Pressurized intraperitoneal aerosol chemotherapy, reasons for interrupting treatment: a systematic review of the literature"],"prefix":"10.1515","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0270-5090","authenticated-orcid":false,"given":"Anne-Cecile","family":"Ezanno","sequence":"first","affiliation":[{"name":"Department of digestive surgery , Begin Military Teaching Hospital , Saint Mand\u00e9 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Malgras","sequence":"additional","affiliation":[{"name":"Department of digestive surgery , Begin Military Teaching Hospital , Saint Mand\u00e9 , France"},{"name":"French Military health Service Academy, Ecole du Val de Gr\u00e2ce , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4793-0008","authenticated-orcid":false,"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[{"name":"Department of digestive surgery , La Piti\u00e9 Salp\u00e9tri\u00e8re Hospital , Paris , France"},{"name":"INSERM , U965 Cart unit , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"2023060816410820031_j_pp-2023-0004_ref_001","doi-asserted-by":"crossref","unstructured":"Alyami, M, H\u00fcbner, M, Grass, F, Bakrin, N, Villeneuve, L, Laplace, N, et al..\u00a0Pressurised intraperitoneal aerosol chemotherapy: rationale,\u00a0evidence, and potential indications. Lancet Oncol 2019;20:e368\u201377. https:\/\/doi.org\/10.1016\/s1470-2045(19)30318-3.","DOI":"10.1016\/S1470-2045(19)30318-3"},{"key":"2023060816410820031_j_pp-2023-0004_ref_002","doi-asserted-by":"crossref","unstructured":"Grass, F, Vuagniaux, A, Teixeira-Farinha, H, Lehmann, K, Demartines, N, H\u00fcbner, M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg 2017;104:669\u201378. https:\/\/doi.org\/10.1002\/bjs.10521.","DOI":"10.1002\/bjs.10521"},{"key":"2023060816410820031_j_pp-2023-0004_ref_003","doi-asserted-by":"crossref","unstructured":"Girardot-Miglierina, A, Clerc, D, Alyami, M, Villeneuve, L, Sgarbura, O, Reymond, MA, et al.. Consensus statement on safety measures for pressurized intraperitoneal aerosol chemotherapy. Pleura Peritoneum 2021;6:139\u201349. https:\/\/doi.org\/10.1515\/pp-2021-0125.","DOI":"10.1515\/pp-2021-0125"},{"key":"2023060816410820031_j_pp-2023-0004_ref_004","doi-asserted-by":"crossref","unstructured":"Sgarbura, O, Villeneuve, L, Alyami, M, Bakrin, N, Torrent, JJ, Eveno, C, et al.. Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): still standardized or on the verge of diversification? Eur J Surg Oncol 2021;47:149\u201356. https:\/\/doi.org\/10.1016\/j.ejso.2020.08.020.","DOI":"10.1016\/j.ejso.2020.08.020"},{"key":"2023060816410820031_j_pp-2023-0004_ref_005","doi-asserted-by":"crossref","unstructured":"Horvath, P, Beckert, S, Struller, F, K\u00f6nigsrainer, A, Reymond, MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer. Clin Exp Metastasis 2018;35:635\u201340. https:\/\/doi.org\/10.1007\/s10585-018-9925-7.","DOI":"10.1007\/s10585-018-9925-7"},{"key":"2023060816410820031_j_pp-2023-0004_ref_006","doi-asserted-by":"crossref","unstructured":"Balmer, A, Clerc, D, Toussaint, L, Sgarbura, O, Ta\u00efbi, A, H\u00fcbner, M, et al.. Selection criteria for pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment in patients with peritoneal metastases. Cancers 2022;14:2557. https:\/\/doi.org\/10.3390\/cancers14102557.","DOI":"10.3390\/cancers14102557"},{"key":"2023060816410820031_j_pp-2023-0004_ref_007","doi-asserted-by":"crossref","unstructured":"Nowacki, M, Alyami, M, Villeneuve, L, Mercier, F, Hubner, M, Willaert, W, et al.. Multicenter Multicentre comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2018;44:991\u20136. https:\/\/doi.org\/10.1016\/j.ejso.2018.02.014.","DOI":"10.1016\/j.ejso.2018.02.014"},{"key":"2023060816410820031_j_pp-2023-0004_ref_008","doi-asserted-by":"crossref","unstructured":"Shamseer, L, Moher, D, Clarke, M, Ghersi, D, Liberati, A, Petticrew, M, et al.. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647. https:\/\/doi.org\/10.1136\/bmj.g7647.","DOI":"10.1136\/bmj.g7647"},{"key":"2023060816410820031_j_pp-2023-0004_ref_009","doi-asserted-by":"crossref","unstructured":"Alyami, M, Gagniere, J, Sgarbura, O, Cabelguenne, D, Villeneuve, L, Pezet, D, et al.. Multicentric initial experience with the use of the\u00a0pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur\u00a0J\u00a0Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2017;43:2178\u201383. https:\/\/doi.org\/10.1016\/j.ejso.2017.09.010.","DOI":"10.1016\/j.ejso.2017.09.010"},{"key":"2023060816410820031_j_pp-2023-0004_ref_010","doi-asserted-by":"crossref","unstructured":"De Simone, M, Vaira, M, Argenziano, M, Berchialla, P, Pisacane, A, Cinquegrana, A, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin, cisplatin, and doxorubicin in patients with peritoneal carcinomatosis: an open-label, single-arm, phase II clinical trial. Biomedicines 2020;8:E102. https:\/\/doi.org\/10.3390\/biomedicines8050102.","DOI":"10.3390\/biomedicines8050102"},{"key":"2023060816410820031_j_pp-2023-0004_ref_011","doi-asserted-by":"crossref","unstructured":"Di Giorgio, A, Schena, CA, El Halabieh, MA, Abatini, C, Vita, E, Strippoli, A, et al.. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): a bidirectional approach for gastric cancer peritoneal metastasis. Surg Oncol 2020;34:270\u20135. https:\/\/doi.org\/10.1016\/j.suronc.2020.05.006.","DOI":"10.1016\/j.suronc.2020.05.006"},{"key":"2023060816410820031_j_pp-2023-0004_ref_012","doi-asserted-by":"crossref","unstructured":"Di Giorgio, A, Sgarbura, O, Rotolo, S, Schena, CA, Bagal\u00e0, C, Inzani, F, et al.. Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma. Ther Adv Med Oncol 2020;12:1\u201310. https:\/\/doi.org\/10.1177\/1758835920940887.","DOI":"10.1177\/1758835920940887"},{"key":"2023060816410820031_j_pp-2023-0004_ref_013","doi-asserted-by":"crossref","unstructured":"Elleb\u00e6k, SB, Graversen, M, Detlefsen, S, Lundell, L, Fristrup, CW, Pfeiffer, P, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC)-directed treatment of peritoneal metastasis in end-stage colorectal cancer patients. Pleura Peritoneum 2020;5:20200109. https:\/\/doi.org\/10.1515\/pp-2020-0109.","DOI":"10.1515\/pp-2020-0109"},{"key":"2023060816410820031_j_pp-2023-0004_ref_014","doi-asserted-by":"crossref","unstructured":"Elleb\u00e6k, SB, Graversen, M, Detlefsen, S, Lundell, L, Fristrup, CW, Pfeiffer, P, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study. Clin Exp Metastasis 2020;37:325\u201332. https:\/\/doi.org\/10.1007\/s10585-020-10023-5.","DOI":"10.1007\/s10585-020-10023-5"},{"key":"2023060816410820031_j_pp-2023-0004_ref_015","doi-asserted-by":"crossref","unstructured":"Falkenstein, TA, G\u00f6tze, TO, Ouaissi, M, Tempfer, CB, Giger-Pabst, U, Demtr\u00f6der, C. First clinical data of intraperitoneal aerosol chemotherapy (PIPAC) as salvage therapy for peritoneal metastatic biliary tract cancer. Anticancer Res 2018;38:373\u20138. https:\/\/doi.org\/10.21873\/anticanres.12232.","DOI":"10.21873\/anticanres.12232"},{"key":"2023060816410820031_j_pp-2023-0004_ref_016","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Ellebaek, SB, Fristrup, C, Pfeiffer, P, Mortensen, MB. Pressurized intraperitoneal aerosol chemotherapy with one minute of electrostatic precipitation (ePIPAC) is feasible, but the histological tumour response in peritoneal metastasis is insufficient. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2020;46:155\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2019.08.024.","DOI":"10.1016\/j.ejso.2019.08.024"},{"key":"2023060816410820031_j_pp-2023-0004_ref_017","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Bjerregaard, JK, Fristrup, CW, Pfeiffer, P, Mortensen, MB. Prospective, single-implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol 2018;10:1\u201311. https:\/\/doi.org\/10.1177\/1758835918777036.","DOI":"10.1177\/1758835918777036"},{"key":"2023060816410820031_j_pp-2023-0004_ref_018","doi-asserted-by":"crossref","unstructured":"H\u00fcbner, M, Teixeira Farinha, H, Grass, F, Wolfer, A, Mathevet, P, Hahnloser, D, et al.. Feasibility and safety of pressurized pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis: a retrospective cohort study. Gastroenterol Res Pract 2017;2017:6852749. https:\/\/doi.org\/10.1155\/2017\/6852749.","DOI":"10.1155\/2017\/6852749"},{"key":"2023060816410820031_j_pp-2023-0004_ref_019","doi-asserted-by":"crossref","unstructured":"Giger-Pabst, U, Demtr\u00f6der, C, Falkenstein, TA, Ouaissi, M, G\u00f6tze, TO, Rezniczek, GA, et al.. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer 2018;18:442. https:\/\/doi.org\/10.1186\/s12885-018-4363-0.","DOI":"10.1186\/s12885-018-4363-0"},{"key":"2023060816410820031_j_pp-2023-0004_ref_020","doi-asserted-by":"crossref","unstructured":"Khomyakov, V, Ryabov, A, Ivanov, A, Bolotina, L, Utkina, A, Volchenko, N, et al.. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2). Pleura Peritoneum 2016;1:159\u201366. https:\/\/doi.org\/10.1515\/pp-2016-0017.","DOI":"10.1515\/pp-2016-0017"},{"key":"2023060816410820031_j_pp-2023-0004_ref_021","doi-asserted-by":"crossref","unstructured":"Khosrawipour, T, Khosrawipour, V, Giger-Pabst, U. Pressurized intraperitoneal aerosol chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma. PLoS One 2017;12:e0186709. https:\/\/doi.org\/10.1371\/journal.pone.0186709.","DOI":"10.1371\/journal.pone.0186709"},{"key":"2023060816410820031_j_pp-2023-0004_ref_022","doi-asserted-by":"crossref","unstructured":"Kim, G, Tan, HL, Sundar, R, Lieske, B, Chee, CE, Ho, J, et al.. PIPAC-OX: a phase I study of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal metastases. Clin Cancer Res Off J Am Assoc Cancer Res 2021;27:1875\u201381. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-2152.","DOI":"10.1158\/1078-0432.CCR-20-2152"},{"key":"2023060816410820031_j_pp-2023-0004_ref_023","doi-asserted-by":"crossref","unstructured":"Kurtz, F, Struller, F, Horvath, P, Solass, W, B\u00f6sm\u00fcller, H, K\u00f6nigsrainer, A, et al.. Feasibility, safety, and efficacy of intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: a Registry Study. Gastroenterol Res Pract 2018;2018:2743985. https:\/\/doi.org\/10.1155\/2018\/2743985.","DOI":"10.1155\/2018\/2743985"},{"key":"2023060816410820031_j_pp-2023-0004_ref_024","doi-asserted-by":"crossref","unstructured":"Lurvink, RJ, Rovers, KP, Wassenaar, ECE, Bakkers, C, Burger, JWA, Creemers, GM, et al.. Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC). Surg Endosc 2021;10:4486\u201398. https:\/\/doi.org\/10.1007\/s00464-021-08802-6.","DOI":"10.1007\/s00464-021-08802-6"},{"key":"2023060816410820031_j_pp-2023-0004_ref_025","doi-asserted-by":"crossref","unstructured":"Nadiradze, G, Giger-Pabst, U, Zieren, J, Strumberg, D, Solass, W, Reymond, MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg Off J Soc Surg Aliment Tract 2016;20:367\u201373. https:\/\/doi.org\/10.1007\/s11605-015-2995-9.","DOI":"10.1007\/s11605-015-2995-9"},{"key":"2023060816410820031_j_pp-2023-0004_ref_026","doi-asserted-by":"crossref","unstructured":"Lurvink, RJ, Rovers, KP, Wassenaar, ECE, Bakkers, C, Burger, JWA, Creemers, GM, et al.. Intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase II trial (CRC-PIPAC). Ann Surg Oncol 2021;28:5311\u201326. https:\/\/doi.org\/10.1245\/s10434-020-09558-4.","DOI":"10.1245\/s10434-020-09558-4"},{"key":"2023060816410820031_j_pp-2023-0004_ref_027","doi-asserted-by":"crossref","unstructured":"Sgarbura, O, H\u00fcbner, M, Alyami, M, Eveno, C, Gagni\u00e8re, J, Pache, B, et al.. Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: a multicenter study. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2019;45:2386\u201391. https:\/\/doi.org\/10.1016\/j.ejso.2019.05.007.","DOI":"10.1016\/j.ejso.2019.05.007"},{"key":"2023060816410820031_j_pp-2023-0004_ref_028","doi-asserted-by":"crossref","unstructured":"Struller, F, Horvath, P, Solass, W, Weinreich, FJ, Strumberg, D, Kokkalis, MK, et al.. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C\/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol 2019;11:1\u201312. https:\/\/doi.org\/10.1177\/1758835919846402.","DOI":"10.1177\/1758835919846402"},{"key":"2023060816410820031_j_pp-2023-0004_ref_029","doi-asserted-by":"crossref","unstructured":"Tempfer, CB, Winnekendonk, G, Solass, W, Horvat, R, Giger-Pabst, U, Zieren, J, et al.. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol 2015;137:223\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2015.02.009.","DOI":"10.1016\/j.ygyno.2015.02.009"},{"key":"2023060816410820031_j_pp-2023-0004_ref_030","doi-asserted-by":"crossref","unstructured":"Taibi, A, Sgarbura, O, H\u00fcbner, M, Bardet, SM, Alyami, M, Bakrin, N, et al.. Feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy with or without intraoperative intravenous 5-fluorouracil and leucovorin for colorectal peritoneal metastases: a multicenter comparative cohort study. Ann Surg Oncol 2022;29:5243\u201351. https:\/\/doi.org\/10.1245\/s10434-022-11577-2.","DOI":"10.1245\/s10434-022-11577-2"},{"key":"2023060816410820031_j_pp-2023-0004_ref_031","doi-asserted-by":"crossref","unstructured":"Tabchouri, N, Buggisch, J, Demtr\u00f6der, CR, Thiery, J, Rezniczek, G, Tempfer, CB, et al.. Pressurized intraperitoneal aerosol chemotherapy for colorectal peritoneal metastases. Ann Surg Oncol 2021;28:5275\u201386. https:\/\/doi.org\/10.1245\/s10434-020-09508-0.","DOI":"10.1245\/s10434-020-09508-0"},{"key":"2023060816410820031_j_pp-2023-0004_ref_032","doi-asserted-by":"crossref","unstructured":"Sindayigaya, R, Dogan, C, Demtr\u00f6der, CR, Fischer, B, Karam, E, Buggisch, JR, et al.. Clinical outcome for patients managed with low-dose cisplatin and doxorubicin delivered as pressurized intraperitoneal aerosol chemotherapy for unresectable peritoneal metastases of gastric cancer. Ann Surg Oncol 2022;29:112\u201323. https:\/\/doi.org\/10.1245\/s10434-021-10860-y.","DOI":"10.1245\/s10434-021-10860-y"},{"key":"2023060816410820031_j_pp-2023-0004_ref_033","doi-asserted-by":"crossref","unstructured":"Tempfer, CB, Giger-Pabst, U, Seebacher, V, Petersen, M, Dogan, A, Rezniczek, GA. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol 2018;150:23\u201330. https:\/\/doi.org\/10.1016\/j.ygyno.2018.05.001.","DOI":"10.1016\/j.ygyno.2018.05.001"},{"key":"2023060816410820031_j_pp-2023-0004_ref_034","doi-asserted-by":"crossref","unstructured":"H\u00fcbner, M, Grass, F, Teixeira-Farinha, H, Pache, B, Mathevet, P, Demartines, N. Pressurized intraperitoneal aerosol chemotherapy - practical aspects. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2017;43:1102\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2017.03.019.","DOI":"10.1016\/j.ejso.2017.03.019"},{"key":"2023060816410820031_j_pp-2023-0004_ref_035","doi-asserted-by":"crossref","unstructured":"Farinha, H, Hubner, M, Abba, J, Rao, R, Willaert, W. Treatment response after pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of colorectal origin. Eur J Surg Oncol 2022;48:E114. https:\/\/doi.org\/10.1016\/j.ejso.2021.12.190.","DOI":"10.1016\/j.ejso.2021.12.190"},{"key":"2023060816410820031_j_pp-2023-0004_ref_036","doi-asserted-by":"crossref","unstructured":"Graversen, M, Detlefsen, S, Pfeiffer, P, Lundell, L, Mortensen, MB. Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey. Clin Exp Metastasis 2018;35:103\u20138. https:\/\/doi.org\/10.1007\/s10585-018-9895-9.","DOI":"10.1007\/s10585-018-9895-9"},{"key":"2023060816410820031_j_pp-2023-0004_ref_037","doi-asserted-by":"crossref","unstructured":"Glatz, T, Horvath, P, Lang, SA, Archid, R, Nadiradze, G. Staging laparoscopy and Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: safe access to the abdomen. Pleura Peritoneum 2019;4:20190004. https:\/\/doi.org\/10.1515\/pp-2019-0004.","DOI":"10.1515\/pp-2019-0004"},{"key":"2023060816410820031_j_pp-2023-0004_ref_038","doi-asserted-by":"crossref","unstructured":"Chi, DS, Abu-Rustum, NR, Sonoda, Y, Awtrey, C, Hummer, A, Venkatraman, ES, et al.. Ten-year experience with laparoscopy on a gynaecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. Am J Obstet Gynecol 2004;191:1138\u201345. https:\/\/doi.org\/10.1016\/j.ajog.2004.05.004.","DOI":"10.1016\/j.ajog.2004.05.004"},{"key":"2023060816410820031_j_pp-2023-0004_ref_039","doi-asserted-by":"crossref","unstructured":"Alyami, M, Bonnot, PE, Mercier, F, Laplace, N, Villeneuve, L, Passot, G, et al..\u00a0Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for\u00a0unresectable peritoneal metastasis from gastric cancer. Eur\u00a0J\u00a0Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2021;47:123\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2020.05.021.","DOI":"10.1016\/j.ejso.2020.05.021"},{"key":"2023060816410820031_j_pp-2023-0004_ref_040","doi-asserted-by":"crossref","unstructured":"Girshally, R, Demtr\u00f6der, C, Albayrak, N, Zieren, J, Tempfer, C, Reymond, MA. Pressurized Pressurised intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2016;14:253. https:\/\/doi.org\/10.1186\/s12957-016-1008-0.","DOI":"10.1186\/s12957-016-1008-0"},{"key":"2023060816410820031_j_pp-2023-0004_ref_041","doi-asserted-by":"crossref","unstructured":"Alyami, M, Mercier, F, Siebert, M, Bonnot, PE, Laplace, N, Villeneuve, L, et al.. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2021;47:128\u201333. https:\/\/doi.org\/10.1016\/j.ejso.2019.06.028.","DOI":"10.1016\/j.ejso.2019.06.028"},{"key":"2023060816410820031_j_pp-2023-0004_ref_042","doi-asserted-by":"crossref","unstructured":"Ploug, M, Graversen, M, Pfeiffer, P, Mortensen, MB. Bidirectional treatment of peritoneal metastasis with Pressurized intraperitoneal aerosol chemotherapy (PIPAC) and systemic chemotherapy: a systematic review. BMC Cancer 2020;20:105. https:\/\/doi.org\/10.1186\/s12885-020-6572-6.","DOI":"10.1186\/s12885-020-6572-6"},{"key":"2023060816410820031_j_pp-2023-0004_ref_043","doi-asserted-by":"crossref","unstructured":"Winkler, CS, Sandhu, J, Pettke, E, Merchea, A, Fong, Y, Kumara, HMCS, et al.. Pressurized Pressurised intraperitoneal aerosol chemotherapy, a palliative treatment approach for patients with peritoneal carcinomatosis: description of method and systematic review of literature. Dis Colon Rectum 2020;63:242\u201355. https:\/\/doi.org\/10.1097\/dcr.0000000000001565.","DOI":"10.1097\/DCR.0000000000001565"},{"key":"2023060816410820031_j_pp-2023-0004_ref_044","doi-asserted-by":"crossref","unstructured":"Garg, PK, Jara, M, Alberto, M, Rau, B. The role of pressurized intraperitoneal aerosol chemotherapy in the management of gastric cancer: a systematic review. Pleura Peritoneum 2019;4:20180127. https:\/\/doi.org\/10.1515\/pp-2018-0127.","DOI":"10.1515\/pp-2018-0127"},{"key":"2023060816410820031_j_pp-2023-0004_ref_045","doi-asserted-by":"crossref","unstructured":"Lurvink, RJ, Van der Speeten, K, Rovers, KP, de Hingh, IHJT. The emergence of pressurized intraperitoneal aerosol chemotherapy as a palliative treatment option for patients with diffuse peritoneal metastases: a narrative review. J Gastrointest Oncol 2021;12:S259\u201370. https:\/\/doi.org\/10.21037\/jgo-20-497.","DOI":"10.21037\/jgo-20-497"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/pp-2023-0004\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/pp-2023-0004\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T16:42:01Z","timestamp":1686242521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/pp-2023-0004\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,5,8]]},"published-print":{"date-parts":[[2023,6,8]]}},"alternative-id":["10.1515\/pp-2023-0004"],"URL":"https:\/\/doi.org\/10.1515\/pp-2023-0004","relation":{},"ISSN":["2364-768X"],"issn-type":[{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]}}}